- Investing.com
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Promising Pipeline | Explore Merus N.V.'s innovative multispecific antibody platform, with lead candidate petosemtamab showing strong potential in HNSCC and CRC treatments |
Clinical Milestones | Delve into petosemtamab's impressive Phase 2 results, including a 63% ORR in combination therapy and promising monotherapy outcomes in HNSCC |
Market Potential | Analysts project U.S. peak sales of $3 billion for petosemtamab in HNSCC alone, with additional upside from potential colorectal cancer indications |
Financial Outlook | Despite current losses, Merus maintains a strong cash position. Analyst price targets range from $67 to $109, with profitability expected by 2027 |
Metrics to compare | MRUS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMRUSPeersSector | |
---|---|---|---|---|
P/E Ratio | −18.6x | −1.5x | −0.7x | |
PEG Ratio | 0.20 | 0.08 | 0.00 | |
Price/Book | 8.5x | 2.9x | 2.6x | |
Price / LTM Sales | 127.2x | 46.3x | 3.4x | |
Upside (Analyst Target) | 2.8% | 158.7% | 38.0% | |
Fair Value Upside | Unlock | 16.8% | 5.3% | Unlock |